BCL6B

Across TCGA pan-cancer cohorts, BCL6B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCL6B data layer compared with 24 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BCL6B Mutation is associated with better overall survival. In most high-consensus cancer types, elevated BCL6B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, STAD, and CESC are the cancer types where BCL6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.657	.011	36	view →
STAD	OS	Median	All	0.093	0.670	<.001	24	view →
CESC	DFS	Median	II,III,IV	0.188	0.785	.001	18	view →
LUAD	OS	Median	II,III,IV	0.150	0.709	.001	12	view →
COAD	DFS	Median	All	0.155	0.568	.026	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BCL6B–UCEC (OS)

Open the UCEC breakdown →